retatrutide clinical trial retatrutide drug Results: 28.3% Weight Loss Data Trial of next-gen weight-loss drug

The GLP-1 shortage challenges are exacerbated by a lack of accurate, up-to-date, and accessible GLP-1 supply information

The association was still present when patients on medications for opioid, alcohol, or nicotine use disorder were excluded, with a 44% lower risk during active GLP-1 use and a 28% lower risk after discontinuation

2019 Feb 14;6(1):93-99

data curation, Nusly Andres Montenegro and Sidnee Molina Gutierrez

As the feasibility of large-scale production, for example, the size and shape, ratios of the weight and volume to the reaction volume, and stirring conditions employed in this study would be reproducible when increasing the reaction volume to 1,000 mL for repeated batch reactions of NsPCS immobilized on both the cellulose sponge and MCC

Personalizing your meal timing and composition based on your genetic predispositionsthrough testing like PlexusDx's Precision Peptide Genetic Testcan optimize which GLP-1-stimulating foods work most effectively for your unique biology